Know Cancer

forgot password

Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial

18 Years
Open (Enrolling)
Colon Cancer

Thank you

Trial Information

Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial

Patients with histological confirmed colon adenocarcinoma compatible with clinical stage II
or III are eligible for study screening. Receipt of a signed informed consent and study
inclusion should be done within 15 days after histological diagnosis. A usual workup for
preoperative staging of colon cancer must be done not more than 1 month before study
inclusion and include CEA assessment, positive histological sample for colon adenocarcinoma
and chest and abdominal CT scan. After receipt of the written consent, the patient undergoes
baseline PET/CT scan and donates blood samples for CTC and SNP analyses. Delay between
baseline examinations and histological diagnosis must not exceed 21 days. The baseline
examinations should be done within 1 week before beginning of the first course of FOLFOX
chemotherapy. Thirteen to 15 days after chemotherapy, the PET/CT and blood sampling for CTC
analysis are repeated. Standard surgery follows after 15 days but no more than 30 days from
Day 1 of preoperative chemotherapy. Two frozen tissue cores are obtained during surgery and
sent immediately in dry ice shipping to the central Tumour Bank (Jules Bordet Institute) or
stored locally at -80°C to be sent in batches to the central tumour bank. Thereafter, the
patient receives standard care, according to tumour pathological stage. In fully eligible
patients, FOLFOX chemotherapy should be started not more than 45 days after surgery. In
stage III patients otherwise ineligible, recommendation is to start FOLFOX chemotherapy
within 45 days after surgery although such patients will not be included in the primary
analysis. Treatment in case of stage II or stage IV colon cancer is left at investigator's
discretion. Eleven courses of adjuvant FOLFOX are foreseen, in order to match the usual
recommendation coming from the Mosaic Trial.

Follow-up procedures after completion of adjuvant treatment will follow standard European
clinical recommendations for stage II and III patients. Clinical follow-up data will be
obtained for all patients, including those with stage II disease, with a minimum follow-up
time of three years.

Inclusion Criteria:

- Age 18 years or older

- Clinical/radiological evaluation compatible with stage III colon adenocarcinoma

- No prior chemotherapy

- No prior abdominal or pelvic irradiation

- WHO performance status 0 or 1

- Effective contraception during the study and the following six months

- Signed informed consent obtained prior to any study-specific screening procedures

- Tumour considered as curatively resectable (R0) based on standard preoperative

- White blood cell count ≥ 3×109/L with neutrophils ≥ 1.5×109/L, platelet count ≥
100×109/L, haemoglobin ≥ 9 g/dL (5.6 mmol/L)

- Direct bilirubin ≤ 1.5×ULN; ASAT and ALAT ≤ 2.5×ULN; Alkaline phosphatase ≤ 2.5×ULN;
Serum creatinine ≤ 1.5×ULN

- Delay between assessment of screening criteria and first PET/CT < 21 days

- Blood glucose < 150 mg/dl at the time of FDG administration. Insulin or oral
anti-diabetic medication is not allowed on the days of PET/CT imaging.

- Compliance to the first chemotherapy course to be administered before surgery

- Delay between the first PET/CT imaging and the start of neoadjuvant FOLOFX < 7 days

- Second PET/CT imaging performed on D14 (range: D13-D15, with D1 as the first day of
chemo administration)

- Delay between the second PET/CT and surgery < 7 days

- Stage III (ypTNM) as assessed after surgery

- CEA < 1.5 x ULN 1 month after surgery -

Exclusion Criteria:

- Major surgical procedure, open biopsy or significant traumatic injury within 28 days
prior to screening. Incompletely healed wounds or anticipation of the need for major
surgical procedure during the course of the study

- Any suspicion of metastatic disease

- Rectal cancer located within 15 cm from the anal verge by endoscopy or under the
peritoneal reflection at surgery

- Inflammatory bowel disease

- Pregnancy (absence to be confirmed by ß-hCG blood test) or breast-feeding

- History or current central nervous system disease or peripheral neuropathy

- Hypersensitivity to any of the components of study treatments

- Previous malignancy in the last five years except basal-cell carcinoma of the skin or
in situ cervical carcinoma

- Clinically relevant coronary artery disease or history of myocardial infarction in
the last 6 weeks or high risk of uncontrolled arrhythmia

- Medical, geographical, sociological, psychological or legal conditions that would not
permit the patient to complete the study or sign informed consent

- Any significant disease which, in the investigator's opinion, would exclude the
patient from the study

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS.

Outcome Time Frame:

Within 3 years after completion of adjuvant chemotherapy

Safety Issue:


Principal Investigator

Alain Hendlisz, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Jules Bordet Institute, Brussels, Belgium


Belgium: Federal Agency for Medicinal Products and Health Products

Study ID:




Start Date:

November 2009

Completion Date:

November 2014

Related Keywords:

  • Colon Cancer
  • Colonic Neoplasms